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OBJECTIVES We sought to characterize stress-induced left ventricular systolic dysfunction in patients with
hypertrophic cardiomyopathy (HCM).
BACKGROUND Myocardial ischemia and diastolic dysfunction occur in patients with HCM. We hypothe-
sized that, in the setting of transient myocardial ischemia, left ventricular systolic dysfunction
occurs during exercise and dobutamine stress.
METHODS We studied 39 patients with HCM but without obstructive symptoms at rest or coronary
artery disease. A continuous ventricular function monitor equipped with cadmium telluride
detectors (VEST) was used to evaluate left ventricular function during supine bicycle
ergometer exercise. Dobutamine stress echocardiography (DSE) was also performed. The left
ventricular ejection fraction (LVEF) and regional wall motion were determined from
echocardiographic images.
RESULTS Changes in the LVEF correlated between exercise and dobutamine stress (r 5 0.643, p ,
0.0001). The LVEF decreased more than 5% at peak exercise in 17 of patients (group II),
while the other patients had normal responses (group I). New regional wall motion
abnormalities during dobutamine infusion were detected in 18 of 110 (16.4%) segments in
group I and 42 of 85 (49.4%) segments in group II. Decreased or unchanged regional wall
motion occurred more frequently in hypertrophied segments than in nonhypertrophied
segments (p , 0.0001). There were significant inverse correlations between the LVEF
responses during both stresses and the number of abnormal segments noted during
dobutamine stress in all patients (VEST: p , 0.005; DSE: p , 0.0005). Signs of left
ventricular obstruction were observed in 11 of 39 patients during DSE. However, there was
no significant correlation between the LVEF response and the dobutamine-induced left
ventricular pressure gradient.
CONCLUSIONS Exercise-induced systolic dysfunction occurred in 50% of patients with HCM. In these
patients, regional wall motion abnormalities were present in hypertrophied segments. (J Am
Coll Cardiol 2000;36:856–63) © 2000 by the American College of Cardiology
Exertional dyspnea and chest pain are common complaints
in patients with symptomatic hypertrophic cardiomyopathy
(HCM). One cause of these symptoms might be myocardial
ischemia, affecting either a portion or all of the left ventricle
(LV). Myocardial ischemia without significant coronary
artery stenosis in the setting of HCM has been demon-
strated by fixed or reversible exercise thallium perfusion
defects (1–4), myocardial lactate production during atrial
pacing (5) and positron emission tomography (6,7).
If an ischemic process contributes to the clinical mani-
festations of HCM, LV dysfunction during exercise might
provide critical information concerning the pathophysiology
of HCM. We have previously demonstrated that the LV
ejection fraction (LVEF) decreases during exercise in some
patients with nonobstructive HCM using a continuous
ventricular function monitor equipped with cadmium tellu-
ride detectors (VEST) (8). Although LV functional reserve
can be assessed with the VEST, it is difficult to determine
whether the abnormal responses occur because of diffuse or
focal wall motion abnormalities. However, echocardio-
graphic assessment of the LV may be used to analyze
regional wall motion during stress-induced ischemia and
has been widely employed for the detection of coronary
artery disease (CAD; 9,10). Furthermore, it is possible to
measure the intraventricular pressure gradient using Dopp-
ler ultrasound (11–13).
In this study we evaluated stress-induced LV dysfunction
in patients with HCM. In addition, we compared results
obtained by exercise stress and dobutamine stress using
VEST and dobutamine stress echocardiography (DSE).
METHODS
Study patients. Forty-five consecutive patients with HCM
were considered for entry in the study. The diagnosis of
HCM was based on the echocardiographic demonstration
of a nondilated, hypertrophied LV in the absence of other
cardiac or systemic diseases that could cause LV hypertro-
phy. Coronary angiography and cardiac catheterization were
performed in all of the patients. Six patients were excluded
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from the study for the following reasons: four patients had
entered the dilated phase of HCM, midventricular obstruc-
tion at rest was present in one patient, and one patient had
undergone pacemaker implantation. The remaining 39 pa-
tients (33 men, 6 women; 23 to 74 years of age [mean age:
51 years]) were studied. All patients were in sinus rhythm,
had angiographically normal coronary arteries and normal
LV systolic function at rest. None of the patients had an LV
systolic pressure gradient under basal conditions. Twenty-
four patients were in New York Heart Association func-
tional class I, and 15 were in class II. Written informed
consent was obtained from all patients. All cardioactive
drugs were discontinued at least 24 h before stress testing.
VEST. To evaluate ventricular function during exercise, a
continuous radionuclide ventricular function monitor
(RRG-607, Aloka, Tokyo, Japan) was used. The VEST
system consists of a cadmium telluride detector, preampli-
fier, portable acquisition unit and battery. The patient’s red
blood cells were labeled in vivo with 740 to 925 MBq (20 to
25 mCi) of technetium-99m. Electrocardiographic elec-
trodes were positioned to record a standard 12-lead electro-
cardiography (ECG). With the patient in the supine posi-
tion; the plastic vestlike garment was placed on the patient’s
chest, and the VEST detector was positioned over the LV
blood pool using gamma camera guideline and locked into
the garment. The VEST records sequential 50-ms radionu-
clide emissions from the LV, and the data are transferred to
a laptop personal computer (LT11, NEC, Tokyo, Japan).
During data sampling, a beat-to-beat three-point LV
smoothed time-activity curve was displayed in real time. A
fixed percentage of the background activity (70% of the
end-diastolic counts) was used as a baseline. Data were
summed at 20-s intervals to calculate the end-diastolic and
end-systolic counts. For the calculation of relative LV
volume, the resting end-diastolic volume (EDV) in the
supine position at the beginning of the study was defined as
100%. All other EDV and all end-systolic volumes (ESV)
were calculated relative to the initial EDV.
After a 5-min rest period, patients performed supine
bicycle ergometer exercise at an initial workload of 25 W,
which was increased by 25-W increments every 2 min. The
12-lead ECG and blood pressure were recorded every min
during the test. Criteria for terminating the test included: 1)
$4-mm ST segment depression 80 ms after the J point, 2)
severe chest pain or fatigue, or 3) achieving the age-
predicted maximal heart rate. All data were recorded within
10 min of the termination of exercise.
Changes in the LVEF during exercise were divided into
four types, as described in a previous study (14). In type 1,
the LVEF increased by more than 5%, and the increase was
maintained during peak exercise. In type 2, the LVEF
initially increased by more than 5%, but the increase could
not be maintained during peak exercise. In type 3, there was
no significant change in LVEF. In type 4 there was a
persistent decrease in LVEF .5% until the end of exercise.
The 5% cutoff was used because changes in LVEF caused by
positioning or other errors was ,5% in a previous study
(14).
DSE. Routine echocardiographic studies were performed
in all patients to identify the regions of LV hypertrophy.
Studies were performed using a digital ultrasound system
(SSA-380A, Toshiba, Tokyo, Japan) with a 3.7 MHz
transducer. After resting images were obtained, dobutamine
was administered intravenously at incremental doses of 5,
10, 20 and 30 mg/kg/min at 5-min intervals. Echocardio-
graphic imaging was performed at each dose of dobutamine
and recorded on videotape for subsequent analysis. Contin-
uous wave Doppler examination of the LV cavity was
performed at each dose from the apical window. The
12-lead ECG and blood pressure were monitored at 1-min
intervals. The infusion was terminated after the maximal
dose was reached or for one of the following reasons: 1)
$2 mm ST segment depression, 2) development of signif-
icant side effects or arrhythmias, 3) achievement of 85% of
the age-predicted maximal heart rate, 4) systolic blood
pressure .250 mm Hg, or 5) a significant fall in systolic
blood pressure (.20 mm Hg) from the baseline.
Echocardiographic analysis. Left ventricular wall thick-
ness at end-diastole was measured by B mode echocardiog-
raphy. The LV was divided into five segments (anterior
wall, septal wall, posterior wall, lateral wall and apical wall;
Fig. 1). Hypertrophy was defined as a wall thickness
$15 mm.
Videotaped echocardiographic images were digitized, and
a quad screen format (Freeland System; TomTec Imaging
System, Boulder, Colorado) was used to compare rest
images with stress images in the same imaging planes.
Regional wall motion was graded for each segment using
the following scale: 0 5 dyskinetic, 1 5 akinetic, 2 5
hypokinetic, 3 5 normal and 4 5 hyperkinetic. During
DSE regional wall motion assessments represent the con-
sensus of two experienced observers who were blinded to the
clinical data.
Left ventricular volume was assessed in the same blinded
fashion. End-diastolic and end-systolic images from the
apical four- and two-chamber views were traced using a
Cardio 500 (Kontron, Munich, Germany) image processing
computer. The end-diastolic image was defined as the
image coinciding with the onset of the QRS complex, and
Abbreviations and Acronyms
ANOVA 5 analysis of variance
CAD 5 coronary artery disease
DSE 5 dobutamine stress echocardiography
ECG 5 electrocardiography
EDV 5 left ventricular end-diastolic volume
ESV 5 left ventricular end-systolic volume
HCM 5 hypertrophic cardiomyopathy
LV 5 left ventricle or ventricular
LVEF 5 left ventricular ejection fraction
VEST 5 continuous ventricular function monitor
equipped with cadmium telluride detectors
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end-systole was defined as the image with the smallest
cavity area. Left ventricular volume and LVEF were calcu-
lated from an average of three consecutive cardiac cycles
using the biplane Simpson’s rule method.
An intraventricular gradient was defined as the develop-
ment of a late-peaking LV Doppler velocity profile. The
pressure gradient was calculated using a modification of the
Bernoulli equation: deltaP 5 4V2, where deltaP is the
instantaneous pressure gradient (in mm Hg) and V is the
measured maximal flow velocity (in m/s).
Statistical analysis. The results are expressed as the
mean 6 standard deviation. Differences between groups I
and II at baseline were analyzed by Student unpaired t test,
Fisher exact test and the Mann-Whitney U test. Hemody-
namic changes during exercise stress and dobutamine stress
tests were analyzed using two-way repeated measures anal-
yses of variance (ANOVA). Correlations between different
parameters were assessed by linear regression analysis. A p
value ,0.05 was considered statistically significant. Statis-
tical analyses were performed using the StatView applica-
tion (version 4.5, Macintosh; Abacus Concepts, Berkeley,
California).
RESULTS
Hemodynamic and LV response during exercise. There
were significant increases in heart rate, blood pressure and
rate-pressure product during exercise. The relative EDV
and ESV increased significantly during peak exercise.
Therefore, the mean LVEF did not differ significantly
between rest (65.8 6 7.0%) and peak exercise (63.5 6
12.0%).
However, the individual LVEF responses to exercise were
highly variable. Ten patients had the type 1 LVEF response,
14 patients had the type 2 response, 5 patients had the type
3 response, and 10 patients had the type 4 response. Ten
patients with the type 4 response and 7 patients with the
type 2 response had a decrease in LVEF of more than 5%
until they achieved peak exercise. To evaluate stress-induced
LV dysfunction in greater detail, patients were divided into
two groups. Group I had a normal response, and group II
had a decrease in ejection fraction .5%. All patients
underwent DSE. Table 1 summarizes the clinical, radionu-
clide and baseline echocardiographic characteristics of the
two groups. There were no significant differences between
the groups, except for the proportion of female patients
(p 5 0.002). Chest pain and ischemic ST segment depres-
sion during exercise test occurred more frequently in group
II (chest pain, p , 0.05; ST depression, p , 0.001).
Comparison of hemodynamics with exercise and dobut-
amine stress (Table 2). Although the heart rate, blood
pressure, rate-pressure product and LVEF were similar at
rest for the two types of stress test, the hemodynamic
responses were blunted during DSE compared with VEST.
The LV volumes increased during VEST but decreased
during DSE (p , 0.0001, ANOVA). Although LVEF
responses during DSE were smaller than those during
VEST, the change in LVEF during DSE significantly
correlated with the change during VEST (r 5 0.643, p ,
0.0001; Fig. 2).
DSE. The maximum dose of dobutamine (30 mg/kg/min)
was infused in 35 patients. Dobutamine infusion was
stopped at 20 mg/kg/min because of the development of
severe chest pain in two patients, severe palpitations in one
patient and hypotension (.40 mm Hg decrease from
previous stage) in one patient. In 26 patients (67%), dobut-
amine administration did not elicit cardiac symptoms. Seven
patients (18%) developed angina, and four patients (10%)
developed severe palpitations. In two patients, the systolic
blood pressure decreased more than 30 mm Hg.
The heart rate, rate-pressure product and EDV indexes
during dobutamine stress testing were not different between
the two groups (Table 3). The change in LVEF during
DSE was significantly different in the two groups (p ,
0.0001, ANOVA; Table 3, Fig. 3). In group I, the LVEF
increased from baseline during low dose (10 mg/kg/min)
dobutamine infusion (from 62.1 6 6.9% to 70.5 6 8.5%).
The increase in LVEF was maintained during the infusion
of the maximum dobutamine dose (72.4 6 10.4%). In group
II, the LVEF did not change between baseline and low dose
dobutamine infusion (62.5 6 8.5% and 64.3 6 8.4%,
respectively) but decreased with the maximal dobutamine
dose (56.4 6 9.4%).
New regional wall motion abnormalities developed with
dobutamine infusion in both groups (Fig. 4). In group I, the
regional wall motion score increased in 78 of the 110
segments analyzed (70.9%) and decreased in 1 of the 110
segments with low dose dobutamine infusion. In group II,
Figure 1. Diagrammatic representation of five-segment regional wall
motion analysis in four standard two-dimensional echocardiographic views.
AP 5 apical wall; AW 5 anterior wall; IVS 5 interventricular septum;
LW 5 lateral wall; PW 5 posterior wall.
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the regional wall motion score increased in 42 of the 85
segments analyzed (49.4%) and decreased in 6 of the 85
segments (7.1%) with low dose dobutamine infusion. These
responses were significantly different in the two groups (p ,
0.005). In group I, the regional wall motion score increased
in 1 of 110 segments and decreased in 17 of 110 segments
(15.5%) when the dobutamine infusion was increased to the
maximum dose. In group II, the regional wall motion score
increased in 17 of 85 segments (20.0%) and decreased in 34
of 85 segments (40.0%) when the dobutamine infusion was
increased to the maximum dose. These responses were
significantly different between the two groups (p , 0.0001).
The relationship between regional wall motion responses
during DSE and ventricular wall hypertrophy are summa-
rized in Table 4. A decrease or no change in regional wall
motion score occurred more frequently in hypertrophied
segments than in nonhypertrophied segments (p , 0.0001).
There were significant inverse correlations between the
LVEF response during both stresses and the number of
dysfunctional segments identified by dobutamine stress
(VEST, p 5 0.0016; DSE, p 5 0.0002).
Doppler echocardiography during dobutamine stress.
During DSE, a late-peaking LV Doppler velocity profile
was observed in 11 of 39 patients (28%). In 6 of the 11
patients, systolic anterior motion of the mitral valve oc-
curred during DSE with high peak velocities (.3.0 m/s)
Table 1. Patient Characteristics
Group I
(DeltaEF > 25%)
Group II
(DeltaEF < 25%)
p
Value
Clinical
Age (yr) 51.3 6 12.8 50.2 6 13.0 0.80
Men/Women 22/0 11/6 0.002
HR at rest (beats/min) 60.8 6 8.8 61.5 6 6.2 0.78
SBP at rest (mm Hg) 116.2 6 16.3 120.7 6 17.5 0.42
Treatment (n) 0.60
Beta-blockers 2 4
Calcium channel antagonists 7 5
Sodium channel antagonists 1 2
Diuretics 1 0
No medications 12 8
Radionuclear
Exercise duration (s) 503 6 110 462 6 132 0.34
HR at peak exercise (beats/min) 128 6 21 130 6 23 0.58
SBP at peak exercise (mm Hg) 192 6 35 178 6 27 0.18
DeltaLVEF (%) 6.1 6 7.9 213.3 6 7.4 ,0.0001
LVEF response pattern (n) ,0.0001
Type 1 10 0
Type 2 7 7
Type 3 5 0
Type 4 0 10
DeltaST (mm) 20.5 6 0.5 21.4 6 1.1 ,0.001
End point of exercise test (n) 0.077
Chest pain 3 8 0.026
Fatigue 11 6 0.28
Achieved MHR 8 4 0.31
ST depression . 4.0 mm 1 4 0.10
Echocardiographic
Interventricular septum (mm) 18.5 6 5.6 18.1 6 5.4 0.40
Anterior wall (mm) 18.5 6 4.7 17.3 6 3.3 0.79
Lateral wall (mm) 14.5 6 2.4 14.8 6 3.2 0.29
Posterior wall (mm) 13.9 6 2.5 13.1 6 2.4 0.70
Apical wall (mm) 18.3 6 3.3 16.5 6 2.1 0.07
LVDd (mm) 44.6 6 3.8 45.4 6 5.3 0.61
LVDs (mm) 25.7 6 3.7 26.0 6 5.2 0.83
FS 0.43 6 0.06 0.43 6 0.07 0.91
LAD (mm) 39.1 6 5.5 41.4 6 5.3 0.21
Peak E wave velocity (cm/s) 47.4 6 12.4 43.1 6 10.9 0.27
Peak A wave velocity (cm/s) 42.9 6 10.0 44.2 6 10.7 0.71
E/A ratio 1.19 6 0.50 1.04 6 0.38 0.34
EF (%) 62.1 6 6.9 62.5 6 8.5 0.86
Data presented are mean value 6 SD or a number of patients.
DeltaLVEF 5 LVEF at rest to LVEF at peak exercise; DeltaST 5 ST depression during exercise; EF 5 ejection fraction;
FS 5 fractional shortening; HR 5 heart rate; LAD 5 left atrial dimension; LVDd 5 left ventricular diastolic dimension;
LVDs 5 left ventricular systolic dimension; LVEF 5 left ventricular ejection fraction; MHR 5 maximal heart rate; SBP 5
systolic blood pressure.
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present in the LV outflow tract. In the other five patients,
high intracavitary flow velocities developed. There was no
significant difference in the pressure gradient determined by
the modified Bernoulli equation at the maximum dobut-
amine dose between the two groups (23.8 6 14.9 mm Hg
for group I vs. 29.1 6 24.2 mm Hg for group II; p 5 0.43).
There were no significant correlations between the LVEF
response and the pressure gradient (p 5 0.18) or the systolic
blood pressure response during dobutamine infusion (p 5
0.089).
DISCUSSION
Previous studies have demonstrated that a limited exercise
capacity is common in patients with HCM and is related to
the development of diastolic dysfunction during peak exer-
cise (15–17). However, the LV systolic performance during
loading in patients with HCM has not been determined.
Furthermore, the use of DSE for the assessment of HCM
has only been described in two reports (18,19).
This study examined LV performance in patients with
HCM during exercise or dobutamine stress. The LVEF
decreased in about one-half of the patients with HCM
during both exercise stress and dobutamine stress testing. In
addition, new regional wall motion abnormalities frequently
appeared in these patients during DSE.
Global LV systolic function during stress. Manyari et al.
(20), using radionuclide angiography, reported that one of
five patients with nonobstructive HCM had a decrease in
LVEF during peak exercise. Furthermore, three of six
patients with latent obstruction and five of seven patients
with resting obstruction had a decrease in LVEF during
peak exercise. Among our patients, 17 of 39 had a decrease
in their LVEF of more than 5%. Although 11 of 39 patients
developed latent obstruction during DSE, there was no
significant correlation between the LVEF response and the
presence of latent signs of obstruction. This discrepancy
might be due to differences in patient characteristics, in-
cluding differences in the severity of the disease.
None of our patients had intracavitary pressure gradients
at rest, even with postextrasystolic beats. However, 11
patients developed latent obstruction during high dose
dobutamine infusion. The characteristics of obstruction may
be different during exercise and during dobutamine stress.
In this study, the LV volumes increased during exercise
stress but decreased during dobutamine stress. This decrease
in LV volume in patients with HCM may have facilitated
Figure 2. Correlation between the change in ejection fraction during
VEST and during DSE. Open circles 5 group I; closed circles 5 group
II. DSE 5 dobutamine stress echocardiography; DLVEF 5 change in left
ventricular ejection fraction from baseline to peak stress; VEST 5
continuous ventricular function monitor.
Table 2. Comparison of Hemodynamic Responses Between Exercise and Dobutamine Stress
VEST DSE
p Value (ANOVA)
Stress
Effect
Time
Effect
Stress 3 Time
Interaction
HR (beats/min) 0.014 ,0.0001 0.0028
Baseline 61.4 6 5.8 61.1 6 7.7
Maximal stress 128.9 6 21.9 116.1 6 15.9
SBP (mm Hg) ,0.0001 ,0.0001 ,0.0001
Baseline 126.3 6 19.5 118.2 6 116.8
Maximal stress 186.0 6 32.2 143.6 6 26.2
RPP (beats/minzmm Hgz103) ,0.0001 ,0.0001 ,0.0001
Baseline 7.9 6 1.7 7.3 6 1.5
Maximal stress 24.1 6 6.5 16.7 6 3.8
Relative EDV (%) ,0.0001 0.84 ,0.0001
Baseline 100 100
Maximal stress 110.6 6 6.8 89.4 6 16.4
Relative ESV (%) 0.13 0.63 ,0.0001
Baseline 34.2 6 7.2 38.2 6 8.3
Maximal stress 40.3 6 12.4 30.9 6 13.1
LVEF (%) 0.83 0.16 0.0008
Baseline 65.8 6 7.0 62.1 6 7.6
Maximal stress 63.5 6 12.0 67.9 6 9.0
Data presented are mean value 6 SD.
ANOVA 5 analysis of variance; EDV 5 end-diastolic volume; ESV 5 end-systolic volume; RPP 5 rate-pressure product.
Other abbreviations as in Table 1.
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the development of obstruction. Klues et al. (21) demon-
strated that LV outflow obstruction in patients with HCM
increases after, rather than during, exercise. Furthermore,
rapid changes in preload during recovery are most likely
responsible for the development of outflow obstruction after
exercise. Schwammenthal et al. (22) demonstrated that no
significant correlation exists between the resting and exer-
cise pressure gradient in patients with obstructive cardio-
myopathy. These reports support the hypothesis that LV
obstruction at rest does not always cause the LVEF to
decrease with stress.
There were no significant correlations between the LVEF
response and the pressure gradient or the systolic blood
pressure response in our patients. These findings suggest
that the afterload during stress testing is not always related
to the LVEF response in patients with normotensive HCM.
However, in this study there were no significant changes in
ventricular volumes during dobutamine stress testing in
patients in group II with systolic dysfunction although a
decrease in the LVEF was observed. The reduced preload
reserve in patients with HCM, possibly caused by diastolic
dysfunction, may contribute to the decrease in LVEF.
Kawano et al. (23) reported that 4 of 18 patients with
nonobstructive HCM had poor ventricular responses (an
increase in the fractional shortening #7%) during isopro-
terenol stress echocardiography and that these patients
developed systolic dysfunction during isoproterenol infusion.
Although they concluded that myocardial ischemia was not the
main factor responsible for these findings, we hypothesize that
poor LV systolic responses to stress in patients with HCM are
due to myocardial ischemia. This is because many of our
patients, especially in group II, had exertional angina and
ischemic ST segment depression during exercise.
Figure 3. Left ventricular ejection fraction response during dobutamine
stress echocardiography in group I (open circles) and group II (closed
circles). Circles and bars indicate the mean value 6 SD. Data were
analyzed by two-way repeated measures analysis of variance (group effect
p 5 0.0046, dobutamine effect p 5 0.0002, interaction p , 0.0001).
Table 3. Hemodynamic Responses During Dobutamine Stress Echocardiography
Group I
(DeltaEF
> 25%)
Group II
(DeltaEF
< 25%)
p Value (ANOVA)
Group
Effect
Dobutamine
Effect
Group 3
Dobutamine
Interaction
HR (beats/min) 0.54 ,0.0001 0.87
Baseline 60.8 6 8.8 61.5 6 6.2
Low dose 78.6 6 13.5 81.2 6 15.0
Peak dose 114.8 6 14.4 117.7 6 18.0
SBP (mm Hg) 0.38 ,0.0001 0.037
Baseline 116.2 6 16.3 120.7 6 17.5
Low dose 141.0 6 19.2 132.2 6 24.0
Peak dose 148.6 6 20.5 137.1 6 31.6
RPP (beats/minzmm Hgz103) 0.71 ,0.0001 0.58
Baseline 7.1 6 1.7 7.4 6 1.3
Low dose 11.1 6 2.8 10.8 6 3.2
Peak dose 17.0 6 2.9 16.3 6 4.8
EDVI (ml/m2) 0.06 ,0.0001 0.48
Baseline 42.0 6 7.8 47.6 6 13.0
Low dose 41.4 6 6.6 46.3 6 12.7
Peak dose 36.8 6 8.9 41.6 6 10.1
ESVI (ml/m2) 0.0044 ,0.0001 0.0037
Baseline 16.0 6 4.2 18.6 6 8.9
Low dose 11.7 6 3.8 16.9 6 7.7
Peak dose 10.0 6 4.4 18.0 6 7.2
LVEF (%) 0.0046 0.0002 ,0.0001
Baseline 62.1 6 6.9 62.5 6 8.5
Low dose 70.5 6 8.5 64.3 6 8.4
Peak dose 72.4 6 10.4 56.4 6 9.4
Data presented are mean value 6 SD.
EDVI 5 end-diastolic volume index; ESVI 5 end-systolic volume index; RPP 5 rate-pressure product. Other abbreviations
as in Table 1.
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Regional LV systolic function during stress. We hypoth-
esized that the development of myocardial ischemia is the
primary reason for the decrease in ejection fraction and the
onset of new regional wall motion abnormalities during
exercise and dobutamine stress in patients with HCM.
Cannon et al. (3) reported that 74% of 30 patients with
HCM had reversible thallium defects, and 73% had meta-
bolic evidence of myocardial ischemia during rapid atrial
pacing. Furthermore, 19 of these 30 patients developed
ischemia during isoproterenol infusion. Previous studies
using positron emission tomography have also demon-
strated the presence of myocardial ischemia in patients with
HCM. Nienaber et al. (7) reported that resting myocardial
blood flow is significantly lower in hypertrophied myocar-
dium than it is in nonhypertrophied myocardium and that
blood flow and glucose utilization fail to increase during
exercise in both hypertrophied and nonhypertrophied seg-
ments but become more heterogeneous. Camici et al. (8)
reported that dipyridamole-induced coronary vasodilation is
impaired in both the hypertrophied and nonhypertrophied
myocardium of patients with HCM, especially in patients
with a history of chest pain. In contrast, Perrone-Filardi et
al. (24) demonstrated that myocardial blood flow is normal
in hypertrophied and nonhypertrophied myocardium at rest
although the heterogeneity in regional glucose uptake par-
allels the variability in regional systolic function. These
observations are supported by our findings of a decrease in
LVEF and the presence of regional wall motion abnormal-
ities during exercise and dobutamine stress in patients with
HCM. In our study, the regional wall motion response
during DSE was impaired in hypertrophied myocardium,
and there was a significant correlation between changes in
LVEF and the number of dysfunctional segments. We
hypothesize that stress-induced LV systolic dysfunction in
patients with HCM is caused by myocardial ischemia
occurring predominantly in the hypertrophied myocardium.
Study limitations. Dobutamine stress echocardiography
has some technical limitations. Specifically, quantitative
analysis of regional wall motion was not performed in this
study. However, we have previously used digitized images
and quad screen format to analyze wall motion in a
consistent manner. In this study, DSE produced a lower
peak heart rate and systolic blood pressure than exercise
stress. These differences suggest a different energy require-
ment between the two tests, which may affect the cardiac
workload in some patients during dobutamine infusion. We
did not give atropine during DSE, which has been reported
to increase the sensitivity of the test (25). However, there
was a close correlation between the two tests with respect to
the change in LVEF. Therefore, we believe that LV
performance during the two tests was similar.
We did not measure myocardial lactate extraction or
coronary blood flow during DSE. New regional wall motion
abnormalities that develop during dobutamine stress in
patients with CAD reflect myocardial ischemia because
dobutamine causes a nonhomogeneous increase in coronary
perfusion in patients with CAD (26). However, it is
unknown how dobutamine influences coronary circulation
in patients with HCM. Lazzeroni et al. (27,28) reported
that transient regional dyssynergy dose not occur during
high-dose dipyridamole echocardiography in patients with
HCM in the absence of CAD. In our patients, regional wall
motion abnormalities were commonly observed during
DSE. We believe that this difference is mainly due to the
fact that dobutamine increases myocardial oxygen consump-
tion more than dipyridamole.
Figure 4. Changes in regional wall motion during dobutamine stress echocardiography. The numbers inside the squares represent the number of myocardial
segments. The numbers outside the squares represent the number of segments with changes in regional wall motion from baseline to low dose dobutamine
infusion and from low dose to peak dose dobutamine infusion. Dotted arrows indicate worsening of wall motion during dobutamine stress
echocardiography.
Table 4. Association Between Dobutamine Response for
Regional Wall Motion and Wall Hypertrophy
Regional Wall Motion Score
Wall Thickness
>15 mm <15 mm
Decreased 45 11
Unchanged 16 3
Increased 51 69
p , 0.0001
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Conclusions. We found that LV systolic dysfunction oc-
curred in 44% of patients with HCM. Furthermore, re-
gional wall motion abnormalities frequently developed dur-
ing DSE. However, we found no significant correlation
between the presence of latent signs of obstruction and
stress-induced LV dysfunction. Although the mechanism
responsible for these abnormal responses is not clear, we
hypothesize that stress-induced ischemia causes transient
LV systolic dysfunction.
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